Navigation Links
Generex Provides Additional Details for October 21st Live Video Webcast
Date:10/20/2010

ef="mailto:bradley.smith@muncmedia.com">bradley.smith@muncmedia.com Webcast:

http://investor.generex.com/events.cfmSenior executives are available for media and analyst interviews prior and post the live event. Please contact Bradley Smith to schedule 917.680.6011 or bradley.smith@muncmedia.com

About Generex Biotechnology Corporation Generex is engaged in the research, development, and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  The Company's buccal insulin spray product, Generex Oral-lyn™, which has been approved in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutic vaccines for the treatment of malignant, infectious, allergic, and autoimmune diseases.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Safe Harbor Statement This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements can
'/>"/>

SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Generex Biotechnology Corporation
2. Generex Announces That Adjournment will be Sole Matter Considered at Special Meeting of Stockholders on September 17, 2010
3. Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board
4. Generex Plans Rights Offering to Stockholders Following Reverse Stock Split
5. Generex Scientific Advisor Weighs in on Reverse Stock Split Proposal
6. Generex Provides Additional Reverse Stock Split Information for the Consideration of Stockholders
7. Generex Common Stock to be Quoted on the OTCQB Under the Symbol GNBT Beginning Thursday, October 21, 2010
8. MGT Capital Investments Reports Second Quarter 2008 Financial Results and Provides Update on Recent Developments
9. GeoVax Labs, Inc. Announces Six Month Financial Results and Provides Operational Update
10. Medivation Reports Second Quarter 2008 Financial Results and Provides Corporate Update
11. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... ... 2015 , ... Nearly everyone has heard of the potential of stem cells ... rich source of these cells is teeth—baby teeth that come loose during childhood, wisdom ... to make room for braces. These potent stem cells exist in the dental ...
(Date:7/28/2015)... , July 28, 2015  PDL BioPharma, Inc. ... announced that the Company will release its second quarter ... 2015, on Wednesday, August 5, 2015, after market close. ... that day at 4:30 p.m. Eastern Time to discuss ... call will be available via the webcast link on ...
(Date:7/28/2015)... DUBLIN , July 21, 2015 ... ) has announced the addition of the ... report to their offering. Globally, ... applications including immuno-phenotyping, cell proliferation, cancer, and stem ... in clinical applications primarily because of demand from ...
(Date:7/28/2015)... Tauriga Sciences, Inc. (OTCQB:  TAUG) or ("Tauriga" ... announced that its stockholders approved an increase in the ... Company from 1,000,000,000 to 2,500,000,000 at its Special Meeting ... Law Offices of Nixon Peabody LLP in Midtown Manhattan ... 480,655,929 shares of common stock represented either by proxy ...
Breaking Biology Technology:Advanced Oral and Maxillofacial Surgery (AOMS) in Elmhurst, IL Partners with Provia Labs to make Store-A-Tooth™ Dental Stem Cell Banking Available to their Patients 2PDL BioPharma to Announce Second Quarter 2015 Financial Results on August 5, 2015 2Analysis of the Global Flow Cytometry Market 2012-2018 with a 2014 Base Year and a 2015-2018 Forecast Period 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3
... SAN MARINO, Calif., Feb. 12 Epeius Biotechnologies ... containing an award-winning video and an interactive e-book ... tumor-targeting and cancer-destroying biotechnologies behind the clinical development ... so far only targeted, genetic medicine that has ...
... GuidanceCompany Reiterates 2009 Earnings Guidance and Introduces Q1 2009 ... Cephalon, Inc . (Nasdaq: CEPH ) today ... of $1.727 billion for 2007, exceeding the company,s previously ... the full year 2008 was $3.27. Excluding amortization ...
... coverage to include GPCR directed screening and drug ... Inc. announced today that it has been granted ... for G-Protein-Coupled Receptors and their Signaling Pathways." ... and for identifying drug leads based on their ...
Cached Biology Technology:Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial 2Cephalon's New Product Launches Pace Record 2008 Sales 2Cephalon's New Product Launches Pace Record 2008 Sales 3Cephalon's New Product Launches Pace Record 2008 Sales 4Cephalon's New Product Launches Pace Record 2008 Sales 5Cephalon's New Product Launches Pace Record 2008 Sales 6Cephalon's New Product Launches Pace Record 2008 Sales 7Cephalon's New Product Launches Pace Record 2008 Sales 8Cephalon's New Product Launches Pace Record 2008 Sales 9Cephalon's New Product Launches Pace Record 2008 Sales 10Cephalon's New Product Launches Pace Record 2008 Sales 11Cephalon's New Product Launches Pace Record 2008 Sales 12Cephalon's New Product Launches Pace Record 2008 Sales 13Cephalon's New Product Launches Pace Record 2008 Sales 14Cephalon's New Product Launches Pace Record 2008 Sales 15Cephalon's New Product Launches Pace Record 2008 Sales 16Cephalon's New Product Launches Pace Record 2008 Sales 17Cephalon's New Product Launches Pace Record 2008 Sales 18Cephalon's New Product Launches Pace Record 2008 Sales 19Cephalon's New Product Launches Pace Record 2008 Sales 20Cephalon's New Product Launches Pace Record 2008 Sales 21Odyssey Thera Granted U.S. Patent for Novel GPCR Assay Strategy 2
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/9/2015)... , July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ... today that it will report financial results for the ... 30, 2015 after the close of market. The company ... investors at 2:00 p.m. PT (5:00 p.m. ET), during ... To participate on the live call, analysts and investors ...
(Date:7/8/2015)... LAKES , N.J. and NEW YORK ... Company) and Guidepoint today announced BD ... start-up healthcare companies with free access to Guidepoint,s expert ... several start-ups that are developing cutting-edge technologies to improve ... a dedicated Guidepoint research manager, each start-up entrepreneur will ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... 7, 2008 -- Oncolytics Biotech Inc. (TSX: ONC, ... group led by Dr. Richard Vile of the ... published the results of its work testing the ... reovirus and cyclophosphamide in vivo. The paper, ...
... of Massachusetts Medical School and the Carnegie Institution of ... agreements with Oxford BioMedica (LSE: OXB), a gene ... RNA interference (RNAi) patent rights. The ... Fire, PhD, and Craig C. Mello, PhD, and their ...
... variation and evolution of reproductive systems of flowering plants ... sciences. In a special issue of the International ... the University of Toronto gathers together in a single ... three areas that have seen the most growth: flowers ...
Cached Biology News:U. Mass Medical School and Carnegie announce licensing agreements with Oxford BioMedica 2A special issue of the International Journal of Plant Sciences 2A special issue of the International Journal of Plant Sciences 3
Gloves are 9.25 long, latex, powder free, smooth and ambidextrous....
Request Info...
Prepared with distilled water. Yeast extract solution is autolyzed at 150 g/L....
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Biology Products: